NEO
NeoGenomicsBNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-02
Current thesis
Rising test volumes, stable reimbursement, and successful roll-out of higher‑margin panels drive above‑consensus revenue growth and multiple expansion, supporting upside toward the bull target within 12 months.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +28.4.
What can break
Competition from liquid-biopsy and centralized labs
Momentum
75
Value
41
Sentiment
63
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $13.50 · Bull $16.50 · Bear $9.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-07 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $13.94
Why
Momentum75 · Δ7d +28.4
Value41 · Δ7d -0.0
Sentiment63 · Δ7d -13.4
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
75
34% active weight
Current posture
7d trendImproving
Δ7d
+28.4
Δ21d
+17.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.3
Sentiment
63
33% active weight
Current posture
7d trendSoftening
Δ7d
-13.4
Δ21d
-16.3
Why this grade
Composite grade B. Momentum 75.2 / Value 41.3 / Sentiment 62.6
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.32B
Beta
1.57
Shares Out
129.39M
P/E (TTM) · Derived
-12.1
P/S (TTM)
2.20
P/FCF (TTM) · Derived
-76.17
Rev YoY
+11.9%
EPS YoY
-51.5%
Gross Margin
+43.5%
Op Margin
-17.0%
Net Debt
$154.27M
Current Ratio
3.91
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology